STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sutro Biopharma Inc (STRO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has strong long-term growth potential, supported by positive analyst ratings, a recent price target upgrade, and promising developments in its clinical pipeline. While there are no immediate trading signals or significant insider/hedge fund activity, the company's financials show improving trends, and the recent share offering strengthens its cash position for future growth.
The technical indicators show mixed signals. The MACD is below zero and negatively contracting, suggesting bearish momentum. However, the RSI is neutral at 57.619, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of 15.245, with key resistance levels at 17.137 and 18.305, and support levels at 13.354 and 12.186.
Analysts have upgraded the stock with higher price targets, citing the company's innovative platform and clinical pipeline.
The recent share offering raised $110 million, strengthening the company's financial position.
Financial performance shows YoY improvements in revenue, net income, and EPS.
The MACD indicates bearish momentum.
No significant hedge fund or insider trading activity.
The stock's implied volatility is high, suggesting potential price fluctuations.
In Q3 2025, Sutro Biopharma reported a 13.77% YoY increase in revenue to $9.69 million. Net income improved by 16.54% YoY to -$56.86 million, and EPS increased by 12.61% YoY to -6.7. Gross margin remained stable at 100%.
Analysts are optimistic about Sutro Biopharma. Citizens upgraded the stock to Outperform with a $23 price target, citing the company's platform and cash per share value. Deutsche Bank raised its price target to $51 from $5, highlighting the potential of STRO-004 and dual payload antibody-drug conjugates.
